British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn ...

By Blake Brittain (Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

GSK claims Moderna used its patented mRNA vaccine platform without a license, reaping billions from vaccine sales. The Mandl team at GSK developed a pioneering mRNA platform that has set the ...

Recommended Reading Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio ...

PHILADELPHIA - GSK plc (LSE/NYSE: GSK) revealed new data from its phase III trial for the AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) vaccine, indicating sustained efficacy over three ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...